|
gptkbp:instance_of
|
gptkb:Bastiladon
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
1950s
|
|
gptkbp:atccode
|
J01 EB01
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Gantrisin
|
|
gptkbp:casnumber
|
72-14-0
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C10 H10 N4 O3 S
|
|
gptkbp:class
|
gptkb:Bastiladon
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:community_service
|
safe in children
|
|
gptkbp:composed_by
|
from sulfanilamide
via acylation
via diazotization
|
|
gptkbp:contraindication
|
gptkb:disease
liver disease
pregnancy
|
|
gptkbp:dissolved
|
soluble in water
|
|
gptkbp:dosage_form
|
suspension
injection
|
|
gptkbp:drug_interactions
|
gptkb:methotrexate
gptkb:warfarin
oral hypoglycemics
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sulfisoxazole
|
|
gptkbp:indication
|
bronchitis
otitis media
urinary tract infections
|
|
gptkbp:marketed_as
|
various pharmaceutical companies
|
|
gptkbp:mechanism_of_action
|
inhibits bacterial folic acid synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
bactericidal
bacteriostatic
half Life 6-12 hours
|
|
gptkbp:related_to
|
gptkb:sulfadiazine
gptkb:sulfamethoxazole
|
|
gptkbp:research_areas
|
pharmacology
antibiotic resistance
infectious diseases
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:side_effect
|
gptkb:stevens-johnson_syndrome
dizziness
nausea
rash
hypersensitivity
hemolytic anemia
|
|
gptkbp:used_for
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:sulfanilamide
|
|
gptkbp:bfsLayer
|
7
|